Answers are grounded in this paper and cite their sources.
// Vaibhav Sahai 1 , Amanda J. Redig 2 , Katharine A. Collier 3 , Frank D. Eckerdt 4 and Hidayatullah G. Munshi 3,4,5 1 Department of Medicine, University of Michigan Medical Center, Ann Arbor, MI, USA 2 Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA 3 Department of Medicine, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA 4 The Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL, USA 5 Jesse Brown VA Medical Center, Chicago, IL, USA Correspondence to: Hidayatullah G. Munshi, email: // Keywords : NUT midline carcinoma, breast and prostate cancers, lung cancers, gastrointestinal cancers, brain tumors Received : April 09, 2016 Accepted : May 29, 2016 Published : June 05, 2016 Abstract There is increasing interest in inhibitors targeting BET (bromodomain and extra-terminal) proteins because of the association between this family of proteins and cancer progression. BET inhibitors were initially shown to have efficacy in hematologic malignancies; however, a number of studies have now shown that BET inhibitors can also block progression of non-hematologic malignancies. In this Review, we summarize the efficacy of BET inhibitors in select solid tumors; evaluate the role of BET proteins in mediating resistance to current targeted therapies; and consider potential toxicities of BET inhibitors. We also evaluate recently characterized mechanisms of resistance to BET inhibitors; summarize ongoing clinical trials with these inhibitors; and discuss potential future roles of BET inhibitors in patients with solid tumors.
No takes yet. Share an insight, caveat, or question.
Sahai et al. (2016) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: